Pelage Pharmaceutical
Stimulating hair growth by targeting hair follicle stem cells, activating dormant cells in all forms of alopecia, and delivering a scientifically based, non-invasive, topical small molecule drug platform.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
* | $14.0m Valuation: $83.8m | Series A | |
| Total Funding | 000k | ||
Related Content
Pelage Pharmaceuticals is a pioneering biotech company focused on developing scientifically based treatments for hair loss. Operating in the pharmaceutical and biotechnology market, Pelage Pharmaceuticals aims to serve both men and women who suffer from the emotional and social impacts of hair loss. The company's core product is a novel drug that targets hair follicle stem cells, a groundbreaking approach based on discoveries from UCLA. Unlike existing therapies that address external factors, Pelage's solution activates the unique metabolism of hair follicle stem cells to stimulate hair growth. The business model revolves around the development, clinical testing, and eventual commercialization of this innovative treatment. Revenue is generated through the sale of the drug, once approved, to healthcare providers and directly to consumers.
Keywords: biotech, hair loss, stem cells, hair growth, pharmaceutical, clinical testing, innovative treatment, UCLA discovery, emotional impact, social stigma.